DiagnoCure and Genzyme seal lung cancer test pact
This article was originally published in Clinica
Executive Summary
In a bid to optimise its investigational molecular test for lung cancer, DiagnoCure has licensed from Genzyme worldwide exclusive rights to around 40 genes for potential use in detecting the disease. The genes are intended to supplement those in the original version of DiagnoCure's assay - which uses bronchial aspirate samples - and may also be used to develop new tests that employ other sample types such as blood, sputum, or biopsy materials.